| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Departments of Neurology (Drs. Blum, Dal Pan, Cornblath, and McArthur), Medicine (Dr. Feinberg, Mr. Raines, and Ms. Mayjo), and Epidemiology (Dr. McArthur), Johns Hopkins University, Baltimore, MD.
Supported by the National Institutes of Health grants NS26643, AI76234, AI27668, and RR00722.
Presented in part at the 45th Annual Meeting of the American Academy of Neurology, New York, NY, April 25 to May 1, 1993.
Received September 27, 1994. Accepted in final form August 4, 1995.
Address correspondence and reprint requests to Dr Blum, Department of Neurology, Beth Israel Hospital, 330 Brookline Avenue, GZ-522, Boston, MA 02215.
We studied the features and frequency of sensory neuropathy among 79 HIV-1-infected individuals participating in a multicenter clinical trial of zalcitabine (2 prime 3 prime-dideoxycytidine, or ddC) antiretroviral therapy. The trial compared zalcitabine monotherapy (2.25 mg/day) versus combination therapy (2.25 mg/day ddC) with zidovudine (ZDV, formerly AZT) versus monotherapy with ZDV alone. Neuropathy developed in 34% of ddC recipients but in only 4% of comparable patients treated with ZDV alone--a 7.9-fold increase in the attack rate of neuropathy. Using risk factor analysis, we found that diabetes mellitus was significantly associated with the development of toxic neuropathy (p equals 0.02), and weight loss may contribute to its appearance. Like HIV-associated sensory neuropathy, ddC-related toxic neuropathy is a predominantly sensory, length-dependent, symmetric, painful neuropathy. Dose reduction lessened the severity of symptoms, although objective signs of neuropathy persisted. Patients with subclinical neuropathies or significant neuropathy risks such as diabetes may be poor candidates for ddC therapy.
NEUROLOGY 1996;46: 999-1003.
This article has been cited by other articles:
|
|
 |
|
  K. Hahn, A. Triolo, P. Hauer, J. C. McArthur, and M. Polydefkis Impaired reinnervation in HIV infection following experimental denervation Neurology, April 17, 2007; 68(16): 1251 - 1256. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. L. Cherry, R. L. Skolasky, L. Lal, J. Creighton, P. Hauer, S. P. Raman, R. Moore, K. Carter, D. Thomas, G. J. Ebenezer, et al. Antiretroviral use and other risks for HIV-associated neuropathies in an international cohort Neurology, March 28, 2006; 66(6): 867 - 873. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Schifitto, M. P. McDermott, J. C. McArthur, K. Marder, N. Sacktor, D. R. McClernon, K. Conant, B. Cohen, L. G. Epstein, K. Kieburtz, et al. Markers of immune activation and viral load in HIV-associated sensory neuropathy Neurology, March 8, 2005; 64(5): 842 - 848. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Schifitto, M. P. McDermott, J. C. McArthur, K. Marder, N. Sacktor, L. Epstein, K. Kieburtz, and the Dana Consortium on the Therapy of HIV Dementia Incidence of and risk factors for HIV-associated distal sensory polyneuropathy Neurology, June 25, 2002; 58(12): 1764 - 1768. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Schifitto, C. Yiannoutsos, D. M. Simpson, B. T. Adornato, E. J. Singer, H. Hollander, C. M. Marra, M. Rubin, B. A. Cohen, T. Tucker, et al. Long-term treatment with recombinant nerve growth factor for HIV-associated sensory neuropathy Neurology, October 9, 2001; 57(7): 1313 - 1316. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Martin, G. Solders, A. Sonnerborg, and P. Hansson Antiretroviral therapy may improve sensory function in HIV-infected patients: A pilot study Neurology, June 13, 2000; 54(11): 2120 - 2127. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. McArthur, C. Yiannoutsos, D. M. Simpson, B. T. Adornato, E. J. Singer, H. Hollander, C. Marra, M. Rubin, B. A. Cohen, T. Tucker, et al. A phase II trial of nerve growth factor for sensory neuropathy associated with HIV infection Neurology, March 14, 2000; 54(5): 1080 - 1088. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
